Evirenz 200 Tablet, a prescription drug, is manufactured in various forms such as Tablet. It is primarily used for the treatment of HIV/AIDS. Other than this, Evirenz 200 Tablet has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Evirenz 200 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
The most common side effects of Evirenz 200 Tablet are Fever, Diarrhoea, Headache. Besides the aforementioned side effects, there are other adverse effects of Evirenz 200 Tablet as well, which are listed below. These side effects of Evirenz 200 Tablet are usually temporary and subside with the completion of treatment. If, however, they worsen or do not go away, please speak with your physician.
Furthermore, you should know that effect of Evirenz 200 Tablet is Severe for pregnant women and Mild for women who are breastfeeding. In addition, Evirenz 200 Tablet's effects on the liver, heart and kidney are discussed below in the Evirenz 200 Tablet related warnings section.
Other conditions have been mentioned below in the Evirenz 200 Tablet contraindications section.
Drug reaction of Evirenz 200 Tablet with other medicines has been reported. See below for a complete list.
In addition to these precautions, you may also note that Evirenz 200 Tablet is not safe while driving, and is is not addictive in nature.
Evirenz 200 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Based on research, the following side effects have been observed when Evirenz 200 Tablet is used -
Moderate
Mild
Common
Is the use of Evirenz 200 Tablet safe for pregnant women?
Evirenz should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Evirenz 200 Tablet safe during breastfeeding?
Side effects of Evirenz on breastfeeding women are very mild.
What is the effect of Evirenz 200 Tablet on the Kidneys?
Evirenz is not harmful for kidneys.
What is the effect of Evirenz 200 Tablet on the Liver?
Evirenz may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Evirenz 200 Tablet on the Heart?
Evirenz has very mild side effects on the heart.
Evirenz 200 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Evirenz 200 Tablet unless your doctor advises you to do so -
Is this Evirenz 200 Tablet habit forming or addictive?
Forming a habit of Evirenz 200 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Evirenz 200 Tablet as you may feel sleepy.
Is it safe?
Evirenz 200 Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
There is no benefit of taking Evirenz 200 Tablet for mental disorders.
Interaction between Food and Evirenz 200 Tablet
It is safe to take Evirenz 200 Tablet with food.
Interaction between Alcohol and Evirenz 200 Tablet
Taking alcohol with Evirenz 200 Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Sustiva® (efavirenz)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 481-483
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 809-810